Walton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, L9 7LJ, UK.
Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Qual Life Res. 2023 Nov;32(11):3235-3246. doi: 10.1007/s11136-023-03470-6. Epub 2023 Aug 17.
Reliable measurement of disability in multiple sclerosis (MS) using a comprehensive, patient self-reported scale, such as the World Health Organization Disability Assessment Schedule (WHODAS) 2.0, would be of clinical and research benefit.
In the Trajectories of Outcome in Neurological Conditions-MS study, WHODAS 2.0 (WHODAS-36 items for working, WHODAS-32 items if not working, WHODAS-12 items short-form) was examined using Rasch analysis in 5809 people with MS.
The 36- and 32-item parallel forms, and the cognitive and physical domains, showed reliability consistent with individual or group use. The 12-item short-form is valid for group use only. Interval level measurement for parametric statistics can be derived from all three scales which showed medium to strong effect sizes for discrimination across characteristics such as age, subtype, and disease duration. Smallest detectable difference for each scale was < 6 on the standardised metric of 0-100 so < 6% of the total range. There was no substantial differential item functioning (DIF) by age, gender, education, working full/part-time, or disease duration; the finding of no DIF for time or sample supports the use of WHODAS 2.0 for longitudinal studies, with the 36- and 32-item versions and the physical and cognitive domains valid for individual patient follow-up.
Disability in MS can be comprehensively measured at interval level by the WHODAS 2.0, and validly monitored over time. Routine use of this self-reported measure in clinical and research practice would give valuable information on the trajectories of disability of individuals and groups.
使用全面的、患者自我报告的量表(如世界卫生组织残疾评估量表 2.0[WHODAS 2.0])可靠地测量多发性硬化症(MS)中的残疾,将具有临床和研究意义。
在神经疾病结局轨迹-MS 研究中,使用 Rasch 分析对 5809 名 MS 患者进行了 WHODAS 2.0(用于工作的 WHODAS-36 项、不工作的 WHODAS-32 项、简短的 WHODAS-12 项)评估。
36 项和 32 项平行形式以及认知和身体领域的可靠性与个体或群体使用一致。12 项简短形式仅适用于群体使用。所有三种量表都可以得出用于参数统计的区间水平测量值,并且在年龄、亚型和疾病持续时间等特征之间具有中等至较大的区分能力。每个量表的最小可检测差异在标准化度量的 0-100 之间均<6,即<总范围的 6%。年龄、性别、教育程度、全职/兼职工作以及疾病持续时间均无明显的项目差异功能(DIF);没有时间或样本的 DIF 发现支持 WHODAS 2.0 用于纵向研究,36 项和 32 项版本以及身体和认知领域可用于个体患者随访。
WHODAS 2.0 可全面地以区间水平衡量 MS 中的残疾,并且可以有效地随时间进行监测。在临床和研究实践中常规使用这种自我报告的测量方法,可以提供有关个体和群体残疾轨迹的有价值信息。